Glaukos
GKOS
172.18
+10.59
+6.55%
Glaukos
US · GKOS
#1500 by market cap
Listed 2015
172.18
+10.59
+6.55%
Live - 5344 symbols - heartbeat 250s ago
· 2026-10-08 08:25
Pre-market
172.44
+0.15%
After-hours
172.18
0.00%
Overnight
170.79
-0.81%
- Market cap
- 10.16B
- P/E (TTM)i
- -52.65
- P/Bi
- 14.88
- EPSi
- -3.28
- Div yieldi
- 0.00%
- 52W posi
- 84%
Reader sentiment
Are you bullish or bearish on GKOS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 24.55, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +32.33% YoY
Margins
- Gross margin
- 55.72%
- Operating margin
- -39.33%
- Net margin
- -36.99%
Key ratios & quality
- Altman Z-Scorei
- 24.55
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 181.28M | 236.98M | 224.96M | 294.01M | 282.86M | 314.71M | 383.48M | 507.44M |
| Gross profit | 156.20M | 198.40M | 133.24M | 227.38M | 213.88M | 239.14M | 289.45M | 282.76M |
| Selling & admin expenses | 119.53M | 176.64M | 171.40M | 179.26M | 192.93M | 224.07M | 261.17M | 331.75M |
| Research & development | 49.68M | 68.31M | 85.39M | 101.00M | 123.27M | 138.77M | 136.43M | 150.61M |
| Operating profit | -13.00M | -46.55M | -123.55M | -52.87M | -102.31M | -123.70M | -108.14M | -199.60M |
| Pretax profit | -12.37M | -50.04M | -132.31M | -49.27M | -98.43M | -133.73M | -145.60M | -193.04M |
| Tax | 583.00K | -65.46M | -11.97M | 326.00K | 766.00K | 934.00K | 771.00K | -5.35M |
| Net profit | -12.95M | 15.42M | -120.35M | -49.59M | -99.20M | -134.66M | -146.37M | -187.69M |
| Basic EPS | 0 | 0 | -3 | -1 | -2 | -3 | -3 | -3 |
| Diluted EPS | -0.37 | 0.37 | -2.70 | -1.07 | -2.09 | -2.78 | -2.77 | -3.28 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 106.66M | 124.12M | 133.54M | 143.12M | 150.57M | 185.61M |
| Gross profit | 82.35M | 97.22M | 104.71M | -1.52M | 117.23M | 151.59M |
| Selling & admin expenses | 70.67M | 83.38M | 83.00M | 94.70M | 92.94M | 116.06M |
| Research & development | 32.35M | 36.54M | 38.07M | 43.65M | 44.15M | 51.30M |
| Operating profit | -20.68M | -22.69M | -16.37M | -139.87M | -19.86M | -15.77M |
| Pretax profit | -17.82M | -19.41M | -16.00M | -139.82M | -19.30M | -17.72M |
| Tax | 326.00K | 248.00K | 234.00K | -6.16M | 484.00K | 656.00K |
| Net profit | -18.15M | -19.66M | -16.23M | -133.66M | -19.78M | -18.38M |
| Basic EPS | 0 | 0 | 0 | -2 | 0 | 0 |
| Diluted EPS | -0.32 | -0.34 | -0.28 | -2.32 | -0.34 | -0.31 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 176.57M | 262.88M | 469.44M | 486.13M | 443.86M | 395.46M | 449.79M | 474.98M |
| Cash & ST investments | 140.49M | 173.98M | 404.37M | 414.05M | 352.70M | 295.43M | 318.92M | 278.76M |
| Inventory | 13.28M | 42.58M | 15.81M | 23.01M | 37.84M | 41.99M | 57.68M | 63.56M |
| Total assets | 206.97M | 818.40M | 1.01B | 1.05B | 1.00B | 940.41M | 974.76M | 893.49M |
| Total current liabilities | 30.37M | 57.70M | 49.70M | 63.36M | 72.36M | 74.01M | 75.13M | 101.28M |
| Short-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | 189.42M | 280.03M | 281.40M | 282.77M | -- | -- |
| Total liabilities | 33,110,000.00 | 145,128,000.00 | 338,053,000.00 | 462,547,000.00 | 472,378,000.00 | 478,648,000.00 | 207,825,000.00 | 237,332,000.00 |
| Total equity | 173.86M | 673.27M | 667.45M | 587.15M | 530.01M | 461.77M | 766.93M | 656.16M |
| Retained earnings | -205.13M | -189.71M | -310.06M | -365.21M | -464.41M | -599.07M | -745.44M | -933.13M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 444.54M | 436.07M | 454.77M | 474.98M | 485.75M | 515.78M |
| Cash & ST investments | 298.70M | 274.79M | 273.71M | 278.76M | 276.69M | 286.23M |
| Inventory | 59.46M | 64.62M | 63.86M | 63.56M | 62.38M | 59.31M |
| Total assets | 966.18M | 986.96M | 999.38M | 893.49M | 893.33M | 920.52M |
| Total current liabilities | 68.53M | 79.14M | 87.52M | 101.28M | 89.42M | 102.33M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 202,219,000.00 | 221,846,000.00 | 229,835,000.00 | 237,332,000.00 | 222,398,000.00 | 238,035,000.00 |
| Total equity | 763.96M | 765.11M | 769.54M | 656.16M | 670.93M | 682.49M |
| Retained earnings | -763.59M | -783.24M | -799.47M | -933.13M | -952.91M | -971.29M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 18.86M | -369.00K | -22.99M | 24.71M | -33.08M | -57.76M | -61.32M | -14.79M |
| Depreciation & amortization | 6.26M | 9.86M | 34.61M | 34.42M | 35.95M | 37.98M | 39.92M | 42.35M |
| Free cash flow | 8.55M | -5.09M | -29.92M | -23.08M | -63.35M | -78.01M | -67.62M | -39.06M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 38.60M | 71.76M | 106.16M | 110.12M | 126.60M | 99.32M | 174.36M | 94.65M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -18.52M | 6.98M | -10.09M | 6.84M | -12.53M | 14.82M |
| Depreciation & amortization | 9.31M | 9.62M | 10.19M | 13.23M | 12.88M | 10.14M |
| Free cash flow | -20.46M | 5.80M | -11.73M | -12.68M | -16.49M | 12.09M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 118.99M | 104.65M | 102.08M | 94.65M | 108.08M | 117.60M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -8.30 | 3.64 | -17.95 | -7.91 | -17.76 | -27.16 | -23.83 | -26.38 |
| ROA %i | -6.95 | 3.01 | -13.20 | -4.83 | -9.67 | -13.86 | -15.29 | -20.09 |
| ROIC %i | -9.35 | 3.02 | -13.02 | -4.27 | -9.59 | -14.92 | -17.16 | -23.75 |
| 5-year avg ROE %i | -- | -- | -3.69 | -6.12 | -9.66 | -13.43 | -18.92 | -20.60 |
| EBIT margin %i | -7.17 | -20.03 | -52.54 | -12.21 | -29.95 | -38.16 | -35.35 | -37.13 |
| FCF / sales %i | 4.72 | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.81 | 4.56 | 9.45 | 7.67 | 6.13 | 5.34 | 5.99 | 4.69 |
| Quick ratioi | 5.24 | 3.68 | 8.86 | 7.06 | 5.37 | 4.53 | 5.05 | 3.82 |
| Debt / assetsi | 0.00 | 8.87 | 26.93 | 36.43 | 38.16 | 40.81 | 10.61 | 11.63 |
| LT debt / equityi | -- | 10.79 | 40.57 | 65.12 | 72.16 | 83.10 | 13.48 | 15.83 |
| Interest coveragei | -- | -18.51 | -8.37 | -2.68 | -6.17 | -8.81 | -13.50 | -40.65 |
| Revenue CAGR (3Y) %i | 36.23 | 27.48 | 12.20 | 17.49 | 6.08 | 11.84 | 9.26 | 21.51 |
| Net income CAGR (3Y) %i | -- | 50.53 | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -20.36 | -12.98 | -12.19 | -26.38 | -26.39 | -25.98 |
| ROA %i | -13.02 | -9.73 | -9.10 | -20.09 | -20.36 | -19.72 |
| ROIC %i | -14.83 | -11.46 | -10.83 | -23.75 | -23.69 | -23.29 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -28.48 | -20.00 | -17.42 | -37.13 | -34.45 | -30.67 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.49 | 5.51 | 5.20 | 4.69 | 5.43 | 5.04 |
| Quick ratioi | 5.40 | 4.52 | 4.26 | 3.82 | 4.43 | 4.15 |
| Debt / assetsi | 10.92 | 10.64 | 10.44 | 11.63 | 11.54 | 11.17 |
| LT debt / equityi | 13.81 | 13.73 | 13.56 | 15.83 | 15.36 | 15.07 |
| Interest coveragei | -14.86 | -15.61 | -16.17 | -40.65 | -41.31 | -38.31 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Glaucoma is the largest reported line at 83.61% of revenue, across 2 reported segments.
- The next-largest line, Corneal Health, is a distant second at 16.39% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Glaucoma83.61%
Corneal Health16.39%
Quote time 2026-10-08 08:25:48 · For reference only, not investment advice and not tailored to your situation.